Search company, investor...
Nirogy Therapeutics company logo

Nirogy Therapeutics

nirogytx.com

Founded Year

2014

Stage

Series A | Alive

Total Raised

$18.5M

Last Raised

$16.5M | 2 yrs ago

About Nirogy Therapeutics

Nirogy Therapeutics is a biotechnology company that develops small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. The company was founded in 2014 and is based in Framingham, Massachusetts.

Headquarters Location

175 Crossing Blvd.

Framingham, Massachusetts, 01702,

United States

508-506-9006

Missing: Nirogy Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nirogy Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nirogy Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nirogy Therapeutics is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Nirogy Therapeutics Patents

Nirogy Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Cannabinoids
  • Designer drugs
  • Phenols
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/18/2022

Cannabinoids, Designer drugs, Phenols, Cancer treatments, CB1 receptor antagonists

Application

Application Date

1/18/2022

Grant Date

Title

Related Topics

Cannabinoids, Designer drugs, Phenols, Cancer treatments, CB1 receptor antagonists

Status

Application

Latest Nirogy Therapeutics News

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Jan 12, 2022

Appointment strengthens leadership and expertise to drive lead oncology program into Phase 1 clinical development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role of President and Chief Scientific Officer January 12, 2022 07:30 AM Eastern Standard Time BOSTON--( BUSINESS WIRE )--Nirogy Therapeutics (“Nirogy” or “the Company”), a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that it has appointed life science veteran Simon Pedder, Ph.D., as Chief Executive Officer (CEO) and to the Company’s Board of Directors. Dr. Pedder takes over the position from the founding CEO, Vincent Sandanayaka, Ph.D., who will be transitioning to the role of President and Chief Scientific Officer (CSO). Dr. Pedder brings over 30 years of drug development and commercialization experience to Nirogy. “We are delighted to have Simon join us as CEO and on the Board. He brings considerable development know-how to the team at a pivotal time in the Company’s growth, as we prepare to file our first IND for our lead oncology candidate in the next 12 months,” said Dennis McWilliams, a Partner at Santé Ventures and member of Nirogy’s Board of Directors. “Simon’s guidance and expertise in clinical development, regulatory processes, and the commercialization of products in the oncology and autoimmune spaces will be critical as we advance our pipeline and grow the company.” “I am thrilled to join Nirogy as it pioneers a new approach to drug development by targeting cellular transporters. The breadth of targets that Nirogy’s platform has the potential to reach is exciting as we look to develop new potential medicines to address significant unmet medical needs for people suffering from cancer and autoimmune diseases,” said Dr. Pedder. “It has been a pleasure to lead Nirogy since its inception. I look forward to focusing on the science as CSO and working with Simon to advance our new potential modality of treating cancer and autoimmune diseases,” said Vincent Sandanayaka, Founder, President and CSO of Nirogy. “Simon brings a wealth of team-building and development experience that will help shepherd our company into clinical development and beyond.” Dr. Pedder joins Nirogy from Athenex Pharmaceuticals, where he served as served as Chief Business and Strategy Officer. Prior to Athenex, he was President and CEO of Cellectar Biosciences and of CEO of Chelsea Therapeutics before that. Earlier in his career, Dr. Pedder held senior leadership roles of increasing responsibility at Hoffmann-LaRoche, including as an Officer of the Company, Vice President of Oncology Pharma Business, Life Cycle Leader and Global Project Leader of Pegasys/IFN, and as global Head of the Hepatitis Franchise. Under Dr. Pedder’s leadership, he oversaw the development and commercialization of numerous global brands, such as Tasmar®, Copegus®, Northera®, and Kliseryi® and Pegasys®, which became the standard of care for Hepatitis B and C for over a decade. Dr. Pedder began his career as a faculty member in the Department of Pharmacology in College of Medicine in the University of Saskatchewan, where he obtained his Ph.D. in Clinical Pharmacology. In addition to his Ph.D. in Pharmacology, Simon obtained a Master of Science in Toxicology from Concordia University, a Joint Honors Bachelor of Science in Environmental Studies/Biology from the University of Waterloo and completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School. About Nirogy Nirogy Therapeutics is a biotechnology company based in Boston, MA developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases. For more information, please visit nirogytx.com . Contacts

Nirogy Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nirogy Therapeutics Rank

Nirogy Therapeutics Frequently Asked Questions (FAQ)

  • When was Nirogy Therapeutics founded?

    Nirogy Therapeutics was founded in 2014.

  • Where is Nirogy Therapeutics's headquarters?

    Nirogy Therapeutics's headquarters is located at 175 Crossing Blvd., Framingham.

  • What is Nirogy Therapeutics's latest funding round?

    Nirogy Therapeutics's latest funding round is Series A.

  • How much did Nirogy Therapeutics raise?

    Nirogy Therapeutics raised a total of $18.5M.

  • Who are the investors of Nirogy Therapeutics?

    Investors of Nirogy Therapeutics include Sante, Sporos Bioventures and Small Business Innovation Research Awards.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.